Giuseppe Tarantino
Dana-Farber Cancer Institute, University of Bologna, University of Pennsylvania Wharton School, University of Palermo
Research areas: Medicine · Oncology · Cancer Immunotherapy and Biomarkers · Cutaneous Melanoma Detection and Management · Melanoma and MAPK Pathways
0000-0002-6078-6856
About
CURRENT POSITION
Postdoctoral research fellow Dana Farber Cancer Institute (DFCI)
Associate research Fellow Harvard Medical School and Broad institute
RESEARCH EXPERIENCE
Research Fellow, Centro Interdipartimentale di Ricerche sul Cancro “Giorgio Prodi” - CIRC
EDUCATION AND TRAINING
- PhD in Oncology, University of Bologna (March 2020)
- visiting scientist at Wharton school, UPenn
- MSc Degree in Bioinformatics, University of Bologna: Magna Cum Laude (2015)
- Bsc Degree in Pharmaceutical Biotechnology (2013)
AWARDS
-2024 Winner of the Broad Nucleate Innovation fellowship
-2023 Winner of the AICF fellowship
-2022 Winner of the AICF fellowship
-2019 Winner of the Reactor school of entrepreneurship and innovation for scientists.
-2016 Grant "Giovanna Fatato" Associazione Corri con Giò
-2014 One of the 14 Best students of the school of Science of the Alma Mater Studiorum.
SCIENTIFIC AND RESEARCH ACTIVITY
- Adopting Machine Learning methods for biomarkers discovering and for predicting treatment response from NGS data in oncology
- Structural and dynamical computational characterization of complex biological systems
FUNDED PROJECTS
· NATO-SPS (2016): “Cell Biosensors for Detection of Chemical and Biological Threats”
Employment
-
Dana-Farber Cancer Institute Postdoctoral research fellow2020 - Present
- 2016 - 2020
Education
-
University of Pennsylvania Wharton School2019 - 2019
-
Università degli Studi di Bologna International master degree in Bioinformatics2013 - 2015
-
Università degli Studi di Palermo Biotechnology2010 - 2013
Projects & Funding
Projects & funding information is unavailable.
Publications (37)
- Genomic classification and immune profiling define mucosal melanoma Save
- Genomic, Clinical, and Spatial Predictors of Durable Response to BRAF/MEK Inhibition in BRAF-Mutant Melanoma Save
- Multiomic profiling of a unique in-transit melanoma cohort identifies melanoma differentiation as predictor of tumor progression and therapy response Save
- DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming Save
- The dynamics of hematopoiesis over the human lifespan Save
- Clinico-genomic features predict distinct metastatic phenotypes in cutaneous melanoma Save
- Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab Save
- Overcoming Resistance Mechanisms to Melanoma Immunotherapy Save
- Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma Save
- A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma Save
- Factors Affecting Recurrence and Survival for Patients with High-Risk Stage II Melanoma Save
- Profiling of Natural Killer Interactions with Cancer Cells Using Mass Cytometry. Save
- Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma Save
- A new p65 isoform that bind the glucocorticoid hormone and is expressed in inflammation liver diseases and COVID-19. Save
- Gene Expression Landscape of SDH-Deficient Gastrointestinal Stromal Tumors. Save
- Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AML Save
- Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation Save
- Genetic aberrations and molecular biology of cardiac sarcoma Save
- Successful multidisciplinary clinical approach and molecular characterization by whole transcriptome sequencing of a cardiac myxofibrosarcoma: A case report Save
- Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response Save